40 results about "Gonadotropin" patented technology

The invention belongs to the technical field of medicines, and provides a preparation technology of a sterile injection of rerugolix, which comprises the following steps: redissolving freeze-dried powder consisting of raw material medicines and auxiliary materials by using sterile water for injection, slowly releasing the rerugolix within 2-8 weeks, maintaining the dynamic balance of blood concentration, and preparing the sterile injection of the rerugolix by using the freeze-dried powder to prepare the sterile injection of the rerugolix. Release of gonadotropin is effectively controlled, and the pharmaceutical composition is used for treating indications such as prostatic cancer, uterine fibroma and endometriosis.

The invention provides a polypeptide with an ovary maturation promoting effect and application of the polypeptide in parturition induction of pomfret. The amino acid sequence of the polypeptide is SEQ ID NO: 1. The polypeptide provided by the invention is derived from the GnRH2 gene of the pomfret, and in-vivo experiments prove that the polypeptide can efficiently stimulate the pituitary of the pomfret to secrete gonadotropin, so that the spawning induction time is remarkably shortened, and the spawning rate and the relative spawning amount of parent fish are increased. The polypeptide is strong in species specificity and good in physiological compatibility, does not generate an antibody, avoids side effects of traditional heterologous hormones, is safe and effective, and has a huge potential of being developed into a special spawning induction agent for the pomfret.

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

Described herein are long-acting injectable compositions and methods of using such long-acting injectable compositions. The long-acting injectable composition comprises degarelix (a decapeptide gonadotropin releasing hormone (GnRH) receptor antagonist) or a pharmaceutically acceptable salt thereof. These compositions may also include a biocompatible organic solvent, optionally with one or more additives in a single syringe system.

The invention provides an individualized ovulation promoting scheme and gonadotropin initial dose prediction method based on multi-cycle time sequence modeling and related equipment, and is applied to the technical field of data processing. The method comprises the following steps: firstly, receiving multi-cycle clinical data and basic information of a target user for IVF / ICSI pregnancy-assisted patients, and eliminating unqualified samples to generate an initial data set; after SHAP screening features, training / test set division and SMOTE sample equalization are carried out, an initial model is constructed through a sliding window time sequence module and a multi-algorithm engine; a target model is generated through training and evaluation, and a COS scheme prediction signal and multi-period Gn dose adjustment information are generated in combination with hierarchical classification and weighted integration; calibration information is generated through clinical data verification, after target user information is subjected to standardization processing, an individualized COS scheme and a Gn initial dose are output through a target model, and multi-cycle dynamic accurate recommendation is achieved.

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

An implantable device for delivery of a therapeutic agent is provided. The device includes a core including a core polymer matrix within which is dispersed a therapeutic agent. The therapeutic agent includes one or more GnRH agonist or antagonists or antagonists. The core polymer matrix includes an ethylene vinyl acetate copolymer having a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and / or a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms.

The invention discloses a construction method and application of a grouper oocyte in-vitro vitellogenin Vtg intake system. The method comprises the following steps: (1) preparing fluorescently-labeled vitellogenin Vtg-FITC; and (2) constructing an oocyte in-vitro culture system. The invention further discloses an application of the in-vitro vitellogenin Vtg intake system of the oocyte of the grouper, which is constructed by the method, in researching the regulation effect of gonadotropin on the Vtg intake of the oocyte. According to the method, the egg yolk intake difference caused by ovum surface area difference of ovarian follicles with different sizes is reduced by using oocytes in the same period; according to the invention, a Vtg-FITC marker is adopted as a means for quantifying the quantity of Vtg ingested by oocytes; according to the invention, the effect of gonadotropin on regulating and controlling Vtg intake of oocytes is preliminarily studied through the established in-vitro vitellogenin Vtg intake system of the oocytes of groupers.

The present invention provides a treatment method for improving the estrus rate of cows, comprising the following steps: S1, preparing a daily diet for cows to provide sufficient nutrition for the cows; S2, injecting L-citrulline into the cows at the same time as the first intramuscular injection of gonadorelin into the cows; S3, injecting prostaglandin into the cows intramuscularly for the second time on the 5th to 7th day after the first injection, and injecting L-citrulline into the cows again; S4, injecting gonadorelin into the cows intramuscularly for the third time on the 8th to 9th day after the first injection, and injecting L-citrulline into the cows again. The present invention increases the estrus rate of cows, improves the reproductive efficiency, and increases the benefits of cattle farms by intraperitoneally injecting L-citrulline into cows based on the technology of intramuscular injection of exogenous gonadotropins.

The invention provides a breeding technology and application of pure-color red cattle, and relates to the technical field of animal breeding. The breeding technology of the pure-color red cattle comprises the following specific steps: S1, detecting an MC1R gene c.901Cgt; a T site and a TYRP1 gene c.1267Ggt; according to a homozygous dominant genotype of a site A, a Gaoligong Mountain small yellow cattle female parent and a Tibetan cattle male parent are screened to ensure that the female parent and the male parent carry homozygous red dominant alleles, and meanwhile, intramuscular fat deposition related gene dominant genotype individuals are selected by combining a whole genome association analysis technology; s2, using prostaglandin F2alpha combined with gonadotropin to release hormone treatment, performing estrus cycle synchronization regulation and control on the Gaoligong Mountain small yellow cattle female parent, implementing regular artificial insemination 24-30 hours after thrombus removal, and using the Tibetan Tibetan cattle frozen semen treated by a sperm screening technology. Pure-color red cattle are bred precisely and directionally by adopting innovative technologies such as gene screening, the meat quality is improved, ecological circulation is achieved, and sustainable development of high-mountain animal husbandry is promoted.

This invention provides thiophene-containing cyclic derivatives, their preparation methods, and their pharmaceutical applications. Specifically, this invention relates to a compound of general formula (I) and its pharmaceutically acceptable salt, their preparation methods, and their use as gonadotropin-releasing hormone (GnRh) receptor antagonists, wherein the definitions of each substituent in general formula (I) are the same as those in the specification.

A messenger ribonucleic acid (mRNA) vaccine for Bandavirus dabieense (DBV) and a preparation method thereof are provided. The provided mRNA molecule is an mRNA obtained by cloning an optimized DBV glycoprotein gonadotropins (Gn) sequence into a pGEM-3Zf (+) mRNA vaccine vector, linearizing a plasmid via enzyme digestion, and capping and adding a poly(A) tail through an in vitro transcription enzyme method. The mRNA is encapsulated using a lipid nanoparticle delivery system to obtain the mRNA vaccine.

The invention provides an oral formulation and the method of preparation thereof for the delivery of a bioactive agent comprising a bioactive agent, a pH modifier, and a solid lipid matrix material, wherein the oral formulation is in the form of solid lipid microparticles formed from the solid lipid matrix material that encapsulates the bioactive agent and the pH modifier. In one embodiment, the bioactive agent is selected from one or more of glucagon-like peptide- 1 (GLP-1) analogues, luteinizing hormone-releasing hormone (LHRH) and gonadotropin-releasing hormone (GnRH), the pH modifier is a weak acid selected from one or more of phosphoric acid, citric acid, lactic acid and malic acid, and the solid lipid matrix material is selected from one or more of glyceryl behenate, glyceryl palmitostearate, tristearin, trimyristin, trilaurin, and stearic acid.

The present application relates to the field of biological products and veterinary medicine, and discloses a method for extracting and purifying blood gonadotropin, which comprises the following steps: 1) adjusting the pH of pregnant mare serum to 4.5-5.0 by using metaphosphoric acid, and performing solid-liquid separation to collect supernatant; 2) precipitating the supernatant by using a first precipitant, and collecting filtrate; 3) precipitating the filtrate by using a second precipitant, collecting precipitate, and drying the precipitate to obtain crude blood gonadotropin; 4) dissolving the crude blood gonadotropin, and sequentially performing first ultrafiltration, affinity chromatography, second ultrafiltration, and cation exchange chromatography to obtain crude blood gonadotropin filtrate; precipitating the crude blood gonadotropin filtrate by using a third precipitant, collecting precipitate, and drying the precipitate to obtain pure blood gonadotropin. The purity of the blood gonadotropin prepared by the extraction and purification method can reach more than 99.9%, the total yield can reach 88.9%, and the titer can reach 11000 IU / mg.

The invention discloses a composition for promoting gonad maturation of wild sal-family large yellow croakers and application of the composition, and belongs to the technical field of aquaculture. Through scientific proportioning of gonadotropin releasing hormone (GnRH) or analogues, polypeptide gonadotropin (FSH, LH) and auxiliary hormone (dopamine receptor antagonist), multi-target activation of an endocrine system of wild parent fish is realized, and synchronous maturation of gonads is promoted. Meanwhile, culture environment parameters such as illumination period, water temperature and salinity are optimized, an ecological environment suitable for sexual maturity is built, stress is reduced, the health of the parent fish is guaranteed, efficient, synchronous and safe sexual maturity of the parent fish is achieved, the breeding efficiency and the fry quality are remarkably improved, an artificial breeding technology of the Pseudosciaena crocea of the sal family is promoted to stride towards the scientization, standardization and industrialization direction, and the economic benefit is increased. And sustainable development of marine fishery resource protection and culture industry is promoted.

The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.

This invention relates to a recombinant single chain chorionic gonadotropin polypeptide, having an amino acid sequence encoding the beta chain and the alpha chain of the equine chorionic gonadotropin linked to one or more sequences that include glycosylation sites, which results in excellent in vitro and in vivo activity. The DNA molecules that encode the recombinant polypeptide are also taught, an expression vector comprising these DNA molecules, compositions comprising the recombinant protein and methods for preparing them are also disclosed.

The disclosure relates to a batch management method for improving the farrowing rate or the number born alive in swine. It includes the following steps: synchronization of estrus in swine are used an exogenous gonadotropin(s) to synchronize follicular development, and then fed with 1-[bis(4-cyanophenyl)alkyl]-1,2,4-triazole after 6-12 hours. Next the gilts or sows are bred in batches after treated with ovulation-inducing drug(s). The disclosure can effectively alleviate decreased farrowing rate and number of piglets born alive in the batch gilts or sows used the fixed-time artificial insemination, without influencing the serum estrogen level, estrus and ovulation time in mated gilts or sows. Therefore, a novel method for improving the reproductive efficiency of gilts or sows will be established, which is valuable for popularizing batch farrowing in swine including with fixed-time artificial insemination.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The utility model discloses a plasma separation device used in the haemotrophin production process, which comprises a supporting seat and a box body rotatably arranged at the top of the supporting seat, the top end of the box body is provided with an injection port, the top of the box body is provided with an installation cover, the top of the installation cover is rotatably connected with a rotating seat, the top of the rotating seat is integrally provided with a boss, and the boss is provided with an opening. A lifting sliding rod capable of being adjusted in a lifting mode is arranged in the boss, the bottom of the lifting sliding rod extends into the box body and is fixedly connected with a lifting base, a disc-shaped brush is installed at the bottom of the lifting base, an annular brush is installed on the outer side of the lifting base, and a brush of the annular brush makes contact with the inner wall of the box body. Due to the design of the lifting sliding rod and the lifting seat, the height of the cleaning brush can be adjusted according to needs, so that the cleaning brush can be better attached to the inner wall of the box body, all-dimensional cleaning without dead corners is achieved, through the combination of the disc-shaped brush and the annular brush, not only can the side wall of the box body be cleaned, but also the bottom of the box body can be particularly cleaned, and the sanitary state of equipment is ensured.

The present invention relates to the field of sexual reproduction technology, and specifically provides a method for improving embryo implantation or reproductive performance. The present invention improves the inflammatory state of the pregnant uterus by applying lactic acid to improve embryo implantation or reproductive performance; in particular, it improves the inflammatory state of the pregnant uterus after exogenous gonadotropin treatment, and finally improves the problems of reduced embryo implantation rate and poor reproductive performance after exogenous gonadotropin treatment. The method described in this application has a wide range of application prospects. For example, it can be used in animal husbandry to achieve reproductive regulation and management of livestock such as pigs, horses, cattle, and sheep, and has high application value.

This invention belongs to the field of assisted reproductive technology, specifically relating to a controlled ovarian stimulation method and supporting drug composition for in vitro fertilization-embryo transfer. The core of this invention does not use GnRH agonists or antagonists throughout the entire process, employing clomiphene combined with individualized, adequate doses of postmenopausal gonadotropins to induce ovulation. A combined packaged drug composition of these two drugs is provided to suit the needs of individuals with high, normal, and low ovarian responses. This method achieves an early ovulation rate of less than 0.2%, an incidence of ovarian hyperstimulation syndrome of less than 1%, and reduces the cost of ovulation induction drugs per cycle by more than 80% compared to existing mainstream methods. It also boasts a stable clinical pregnancy rate and can be widely applied to assisted reproductive ovulation induction treatment for various infertile patients, significantly reducing their economic and time burden.

This invention relates to the field of aquaculture technology, specifically a feed formulation and preparation method for improving the reproductive performance of broodstock tiger prawns. The method includes: determining the specific nutritional requirements of broodstock tiger prawns during gonadal development; screening core animal and plant protein sources and determining their basic mass ratios accordingly; performing targeted biological treatment on the core raw materials to enrich gonadotropin-active small molecules; compounding these with phospholipids, attractants, vitamins, and minerals to form a functional additive combination; mixing the core raw materials and additive combination in proportion, granulating, and adding antioxidants during processing; and finally verifying the formulation effect and confirming the final compound feed through standardized aquaculture trials. The compound feed obtained based on this method can effectively replace traditional live feed, improve broodstock tiger spawning, hatching rate, and larval quality, and has advantages such as balanced nutrition, stable quality, and suitability for large-scale production, solving the industry problems of live feed being prone to pathogens, supply fluctuations, and high costs.

To provide a novel concept for the prevention and treatment of premature ovarian insufficiency (POI).SOLUTION: Disclosed is an application of Lactobacillus plantarum AR501 (AR501) in the manufacture of a drug for the prevention and treatment of premature ovarian insufficiency, which belongs to the biopharmaceutical field. The reserve number of AR501 is CGMCC No. 13910. This strain prevents POI by alleviating estrous cycle disorders, serum hormone disorders, or depressive symptoms. AR501 is used to intervene into POI mice, significantly restoring the estrous cycle of the POI mice and improving serum hormone disorders such as estradiol, gonadotropin-releasing hormone, and anti-Mullerian duct hormone. Intervention with AR501 significantly improves the depressive state of the POI mice and increases their activity. AR501 can be used to manufacture a drug that improves POI, providing a novel concept to the prevention and treatment of POI.SELECTED DRAWING: Figure 1

The application discloses a fermentation process of gonadotropin-releasing hormone hexamer-diphtheria toxin mutant CRM197, and the process comprises the following steps: screening of a fermentation medium and optimization of fermentation conditions. The fermentation medium comprises yeast extract powder, tryptone and NaCl, and the optimization of the fermentation process comprises culture temperature, an inducing agent, concentration of the inducing agent, culture time after induction, adjustment mode of pH of the fermentation liquor, stirring speed, ventilation amount and the like. The fermentation process has the advantages of low production cost, short production cycle (only 12-15 hours are needed), improved expression amount of the target protein per unit of bacteria, and realized high-efficiency expression of the target protein. The GnRH6-CRM197 prepared by the application can be used for immunocastration of various mammals, and has the values of further research and development and good industrialization prospect.

The invention discloses application of cycloastragenol in preparation of a product for treating male sexual dysfunction, and relates to the technical field of biological medicine, sexual dysfunction of male mice caused by high-fat diet, medicine and aging is remarkably improved through intervention of cycloastragenol, the specific expression is that changes of body weight and testis weight are controlled, and the sexual dysfunction of the male mice caused by high-fat diet, medicine and aging is improved. The sperm motility rate is obviously improved, the hormone release level of testosterone and gonadotropin is increased, and the testicular tissue structure is improved.

Described herein are radiotherapeutics that target tumor cells expressing the gonadotropin-releasing hormone receptor (GnRHR) and their use in the treatment and / or diagnosis of cancer.

The invention belongs to the field of aquaculture, and particularly relates to a device and method for increasing the brood amount of brook fishes and promoting the brook fishes to spawn naturally and rapidly, the device comprises a simulated ecological parent fish breeding pond, a spawning inducing facility and a feeding facility, the breeding pond simulates the ecological environment through a specific structure, cobblestones, rhizoma acori graminei and the like, and the breeding pond is used for breeding the brook fishes. The water feeding and discharging facility can generate water flows with different flow speeds. The method comprises the steps of parent fish selection and culture, gonad development promoting feed preparation, staged ecological culture and flowing water stimulation simulation, and finally natural and rapid spawning of parent fish is achieved. According to the method, the problems of high injury rate, low egg laying amount and the like caused by insufficient breeding standardization of the brook parent fish and dependence on artificial spawning induction in the prior art are solved, the natural egg laying rate is increased to 90% or above from 30%-35% through ecological simulation and precise breeding, the postpartum death rate of the parent fish is controlled within 6%, and technical support is provided for green and large-scale breeding of the brook fish.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and preparation and application thereof. The composition provided by the present application comprises Ramulus cinnamomi, Poria cocos, Cortex moutan, Semen persicae, Radix paeoniae alba, Radix rubiae, Cornus officinalis, and Rhizoma sparganii. The composition can obviously reduce the prostate index and prostate epithelial thickness of a benign prostatic hyperplasia model rat, and relieve interstitial edema. The experimental results show that the composition can obviously reduce the content of dihydrotestosterone, estradiol, testosterone, gonadotropin-releasing hormone, and rat luteinizing hormone in the prostate serum of a model mouse, and increase the content of follicle-stimulating hormone. The above results show that the traditional Chinese medicine composition can inhibit sex hormone disorder, and has the effect of treating prostatic hyperplasia.

The invention provides a method for regulating and inducing conception of non-pregnant non-oestrus dairy cows. The method is characterized by comprising the following steps: 1) detecting LH and FSH levels and performing staging; 2) carrying out regulation and targeted induction on cows with different LH and FSH stage levels; and 3) artificial insemination. Targeted treatment and precise regulation and control are achieved for high-difficulty breeding cases of 37 sky huai, no oestrus, lasting corpus luteum and uterus residues. The prostaglandin PGF2a + oxytocin + gonadotropin releasing hormone GnRH combined intramuscular injection scheme is adopted, lasting corpus luteum is thoroughly dissolved, residual embryonic tissues in the body are removed, the uterus is purified, the subsequent conception environment quality is remarkably improved, ultrasonic monitoring does not need to be frequently used, individualized and refined hormone regulation is achieved, the conception rate is remarkably increased, and meanwhile the conception time is shortened. The one-birth double-calf rate is stably improved, and the breeding economic benefits are greatly improved.